A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.

StatusRecruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Start date changed from estimate of Jun 1, 2026 to Aug 19, 2026
    • Eligibility criteria expanded, about 30 words
    • Site details revised
  2. Study title shortened, about 8 wordsv3
  3. Trial arms changed: 2 → 3
    • Interventions: DXC006 + ICI (Drug), DXC006 + Platinum (Drug) to Carboplatin (Drug), Cisplatin (Drug), DXC006 (Drug), Toripalimab (Drug)
    • Study title expanded, about 1 word
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase Ib/II, open-label clinical study designed to evaluate the safety, tolerability, preliminary anti-tumor activity, recommended Phase 2 dose (RP2D), pharmacokinetic (PK) characteristics, and immunogenicity of DXC006 in combination with an immune checkpoint inhibitor (ICI) or platinum-based chemotherapy in patients with small cell lung cancer (SCLC).
Trial Details
NCT Number NCT07559929
Lead Sponsor Hangzhou DAC Biotechnology Co., Ltd.
Conditions
(from sponsor)		 Small Cell Lung Cancer
Related terms Small Cell Lung Carcinoma
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov